- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: SALT Study (Switching to the Administration of Lithium Slow -Release Treatment) (clinicaltrials.gov) - Jan 9, 2020
P4, N=85, Terminated,
Trial completion date: Mar 2020 --> Jun 2022 | Trial primary completion date: Dec 2019 --> Dec 2021 N=138 --> 85 | Trial completion date: Dec 2019 --> Sep 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Sep 2019; Sponsor's decision due to slow enrollment rate.
- |||||||||| lithium carbonate / Generic mfg.
Journal: Ultrastructural Changes in Hepatocellular Carcinoma-29 Cells after Treatment with Lithium Carbonate. (Pubmed Central) - Dec 20, 2019
Transmission electron microscopy revealed a decrease in the volume density of the granular endoplasmic reticulum in the cell cytoplasm and an increase in the total numerical and volume density of autophagosomes and autolysosomes and zones of destruction of intracellular organelles. The ability of lithium carbonate to activate intracellular degradation processes in tumor cells and to stimulate cell death can be used to develop new combined strategies in the chemotherapy for hepatocellular carcinoma.
- |||||||||| lithium carbonate / Generic mfg., lithium / Generic mfg.
Journal: Influence of Inorganic Solution Components on Lithium Carbonate Crystal Growth. (Pubmed Central) - Dec 15, 2019
K and Cl may interact with the growing zabuyelite crystals but do not appear to affect zabuyelite nucleation and growth times. These experiments highlight the importance of understanding the solution chemistry on zabuyelite formation in order to predict the efficiency of extraction processes and the purity of the solids.
- |||||||||| Journal: GSK3β Regulates Brain Energy Metabolism. (Pubmed Central) - Dec 6, 2019
In mice treated with the GSK3β inhibitor lithium carbonate, changes in hippocampal energy metabolism are linked to increased PGC-1α. These data highlight a metabolic role for brain GSK3β and suggest that the GSK3β/PGC-1α axis may be important in neuronal metabolic integrity.
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion date, Trial primary completion date: Wake Therapy in the Treatment of Depression (clinicaltrials.gov) - Oct 21, 2019
P=N/A, N=25, Recruiting,
These results support a kinetically controlled reaction pathway to form YMnO phases in assisted metathesis reactions with phase selectivity achievable through changes to reaction atmosphere. Trial completion date: Aug 2020 --> Aug 2022 | Trial primary completion date: Aug 2019 --> Aug 2021
- |||||||||| lithium / generics, memantine / generics
Lithium Sarcosine Delays Disease Onset, Prolongs Survival and Reduces Neurological Deficits in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis by Its Synergistic Dual Therapeutic Mechanisms (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_1103;
Drugs such as riluzole and memantine which delay the disease progression and prolong the life span of SOD1-G93A mice while attenuate NMDA activity...Moreover, lithium sarcosine displayed better rescue/protective effects on MK801-induced hyperlocomotion than lithium chloride...However, both lithium carbonate and lithium sarcosine treatments improved the latency in SOD1-G93A mice and the first significant decrease on rotarod performance was observed at 15 and 16 weeks of age, respectively... Overall, lithium sarcosine has superior physicochemical properties and delays disease onset, prolongs survival and reduces neurological deficits presumably due to its synergistic dual therapeutic mechanisms
- |||||||||| lithium / generics
Lithium Partially Restores Presynaptic Gabaergic Signaling Deficits in the Ank3 W1989R Mouse Model (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_734;
In summary, these results suggest that the ANK3 has an important role in the control of cortical and hippocampal neuronal excitability and dysfunction of this pathway may contribute to the imbalance of circuits seen in BD patients. In addition, our work suggests that lithium may act to increase the presynaptic GABA release in our model, perhaps resulting from increased excitability of parvalbumin-positive interneurons.
- |||||||||| paroxetine / Generic Mfg.
Journal: Alzheimer's Disease and Its Potential Alternative Therapeutics. (Pubmed Central) - Oct 8, 2019
In this review, we discuss general features of AD and several small molecules across different experimental AD drug classes that have been studied for their effects in the context of the molecular targets and responses associated with the AD progression. These drugs include: Paroxetine, Desferrioxamine (DFO), N-acetylcysteine (NAC), Posiphen/-(-)Phenserine, JTR-009, Carvedilol, LY450139, Intravenous immunoglobulin G 10%, Indomethacin and Lithium Carbonate (LiCO).
- |||||||||| lithium / generics
Journal: Dual role of lithium on the structure and self-healing ability of PMMA-silica coatings on AA7075 alloy. (Pubmed Central) - Oct 8, 2019
An analogue mechanism has been proposed for artificially scratched coatings presenting an increase of the impedance modulus after salt spray test compared to the lithium free coating. These results evidence the active role of lithium ions in improving the passive barrier of the PMMA-silica coating and in providing through the self-restoring ability a significantly extended service life of AA7075 alloy exposed to saline environment.
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion date, Trial primary completion date: Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT) (clinicaltrials.gov) - Sep 23, 2019
P2, N=160, Recruiting,
Trial completion date: Aug 2017 --> Sep 2020 | Trial primary completion date: Apr 2017 --> Apr 2020 Trial completion date: Aug 2019 --> Mar 2020 | Trial primary completion date: Apr 2019 --> Dec 2019
- |||||||||| lithium carbonate ER / Generic mfg.
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease (clinicaltrials.gov) - Sep 23, 2019
P1, N=18, Active, not recruiting,
Trial completion date: Aug 2019 --> Mar 2020 | Trial primary completion date: Apr 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Mar 2019 --> Sep 2020
- |||||||||| lithium / generics
Journal: A process for combination of recycling lithium and regenerating graphite from spent lithium-ion battery. (Pubmed Central) - Sep 14, 2019
The regenerated graphite is found to have high initial specific capacity at the rate of 37.2 mA·g (591 mAh·g), 74.4 mA·g (510 mAh·g) and 186 mA·g (335 mAh·g), and with the high retention ratio of 97.9% after 100 cycles, it also displays excellent cycle performance at high rate of 372 mA·g. By this process, copper and lithium can be recovered and graphite can be regenerated, serving as a sustainable approach for the comprehensive utilization of anode material from spent lithium-ion battery.
- |||||||||| risperidone / Generic Mfg., Egis
Clinical, Journal, Real-World Evidence: Real-World Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. (Pubmed Central) - Sep 8, 2019
...In comparison between use and no use among specific agents reaching nominal statistical significance, risperidone long-acting injection (HR, 0.58 [95% CI, 0.34-1.00]), gabapentin (HR, 0.58 [95% CI, 0.44-0.77]), perphenazine long-acting injection (HR, 0.60 [95% CI, 0.41-0.88]), and lithium carbonate (HR, 0.67 [95% CI, 0.60-0.73]) were associated with the lowest risk of psychiatric rehospitalization...The most frequently used antipsychotic treatment, quetiapine fumarate, showed only modest effectiveness (risk of psychiatric rehospitalization: HR, 0.92 [95% CI, 0.85-0.98]; risk of all-cause hospitalization: HR, 0.93 [95% CI, 0.88-0.98])...Results from sensitivity analyses showed consistent beneficial effects only for lithium and for long-acting injections compared with their oral counterparts. Lithium was the most effective mood stabilizer, and long-acting injections the most effective antipsychotics, in preventing hospitalization due to mental or physical illness.
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Treatment of Psychosis and Agitation in Alzheimer's Disease (clinicaltrials.gov) - Aug 20, 2019
P2, N=80, Recruiting,
This effect was observed when comparing 3xTg-AD with Wt mice, suggesting that the presence of AD pathology was required for the lithium modulation of TL. Trial completion date: Apr 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion date, Trial primary completion date: Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia (clinicaltrials.gov) - Aug 19, 2019
P2, N=60, Recruiting,
Trial completion date: Apr 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020 Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Sep 2019 --> Sep 2020
- |||||||||| lithium / generics
Journal: Release of lithium from 3D printed polycaprolactone scaffolds regulates macrophage and osteoclast response. (Pubmed Central) - Jul 17, 2019
Osteoclast activity was greatly suppressed by the lithium incorporation, with a marked effect on gene expression and actin ring formation. Our work demonstrated an effective system for local lithium delivery, confirmed the pronounced effects that lithium has on macrophage and osteoclast response, and sets the stage for further innovations in ion release for targeted tissue engineering.
- |||||||||| lithium / generics
Journal: Dataset of lithium phosphate recovery from a low concentrated lithium-containing solution. (Pubmed Central) - Jul 16, 2019
The concentration of lithium is less than 0.3 g/L after preparation of lithium phosphate. For lithium carbonate recovery by ultrasound, please refer to the full length article entitled "Lithium carbonate recovery from lithium-containing solution by ultrasound assisted precipitation", https://doi.org/10.1016/j.ultsonch.2018.12.025 (Chunlong Zhao et al., 2019) [1].
- |||||||||| lithium / generics
Clinical, Journal, Real-World Evidence: Can lithium salts prevent depressive episodes in the real world? (Pubmed Central) - Jun 15, 2019
The costs of the 1.95 ± 2.38 (mean ± standard deviation) admissions of adherent patients through the 10 years of follow-up were €10,349, while the costs of the 6.25 ± 4.92 admissions of non-adherent patients were €44,547. In clinical practice settings, long-term lithium salts seem to have a preventive effect on depressive symptoms.
- |||||||||| lithium / generics
Journal: Lithium therapeutic dose monitoring in human saliva. (Pubmed Central) - May 22, 2019
There is little number of studies on saliva clinical use in lithium level monitoring. Further studies should base on current data including methods of obtaining saliva and its biochemical analysis, collecting samples in a specific time frame from the last dosage of lithium, as well as inter-subject or intra-subject measurements.
- |||||||||| tacrolimus / generics, lithium / generics
Clinical, Journal, IO Biomarker: Genes involved in stress response influence lithium efficacy in bipolar patients. (Pubmed Central) - May 13, 2019
Further studies should base on current data including methods of obtaining saliva and its biochemical analysis, collecting samples in a specific time frame from the last dosage of lithium, as well as inter-subject or intra-subject measurements. The response to lithium may depend on the variants of genes regulating the HPA axis and stressful life events in bipolar patients.
- |||||||||| lithium / generics
Journal: Lithium response in bipolar disorders and core clock genes expression. (Pubmed Central) - Apr 28, 2019
The response to lithium may depend on the variants of genes regulating the HPA axis and stressful life events in bipolar patients. In LCLs, lithium influences circadian genes expressions with differences in amplitude and kinetics according to the patient's lithium response status.
- |||||||||| Biomarker, Enrollment change, Trial termination: Gao NARASD Lithium Study (clinicaltrials.gov) - Jan 31, 2019
P4, N=25, Terminated,
In LCLs, lithium influences circadian genes expressions with differences in amplitude and kinetics according to the patient's lithium response status. N=50 --> 25 | Active, not recruiting --> Terminated; Lack of funding
- |||||||||| Biomarker, Enrollment closed: Gao NARASD Lithium Study (clinicaltrials.gov) - Nov 2, 2018
P4, N=50, Active, not recruiting,
N=50 --> 25 | Active, not recruiting --> Terminated; Lack of funding Recruiting --> Active, not recruiting
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion date, Trial primary completion date: Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease (clinicaltrials.gov) - Apr 30, 2018
P1/2, N=7, Recruiting,
N=40 --> 0 | Initiation date: Mar 2018 --> Nov 2017 | Enrolling by invitation --> Withdrawn Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Mar 2019
- |||||||||| lithium carbonate ER / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment (clinicaltrials.gov) - Apr 11, 2018
P=N/A, N=11, Completed,
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Mar 2019 Not yet recruiting --> Completed | N=20 --> 11 | Trial completion date: Sep 2016 --> Jun 2017 | Trial primary completion date: Sep 2016 --> Jun 2017
- |||||||||| lithium carbonate ER / Generic mfg.
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder (clinicaltrials.gov) - Feb 9, 2018
P4, N=0, Withdrawn,
Not yet recruiting --> Recruiting | Trial completion date: Sep 2017 --> Jun 2018 | Trial primary completion date: Jul 2017 --> Mar 2018 N=50 --> 0 | Initiation date: Aug 2008 --> Jun 2015 | Trial primary completion date: Dec 2013 --> Dec 2017 | Trial completion date: Dec 2013 --> Dec 2017
|
